ORMP - Oramed Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
7.31
-0.02 (-0.27%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close7.33
Open7.43
Bid6.86 x 3000
Ask8.50 x 1000
Day's Range7.31 - 7.45
52 Week Range6.15 - 11.34
Volume5,674
Avg. Volume18,321
Market Cap105.576M
Beta1.44
PE Ratio (TTM)N/A
EPS (TTM)-0.76
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.50
Trade prices are not sourced from all markets
  • Market Exclusive16 days ago

    For Diabetes Patients, Management Solutions Are As Critical As Medications

    For diabetes sufferers, it’s not just effective medications that are necessary, but effective self-management. The challenge with diabetes, both type 1 and type 2, is not necessarily that the medications we have available today are just not good enough. The problem is, the disease has to be managed constantly, from the moment you wake up […] The post For Diabetes Patients, Management Solutions Are As Critical As Medications appeared first on Market Exclusive.

  • Oramed to Present at Conferences in May
    PR Newswire19 days ago

    Oramed to Present at Conferences in May

    NEW YORK , May 7, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin
    PR Newswirelast month

    Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin

    NEW YORK, April 23, 2018 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has begun screening patients in its 90-day dose-ranging Pivotal Phase 2b HbA1c clinical study of its oral insulin capsule, ORMD-0801. A statistically significant improvement in HbA1c (glycated hemoglobin), a long-term gauge of blood glucose control, was observed in just 28 days of treatment with ORMD-0801 in Oramed's prior Phase 2 study. The study will enroll approximately 240 patients with type 2 diabetes in multiple centers throughout the U.S. The primary end points are safety evaluating adverse and hypoglycemic events, and efficacy specific to HbA1c levels over 90 days of treatment.

  • Oramed to Present at H.C. Wainwright Annual Global Life Sciences Conference
    PR Newswire2 months ago

    Oramed to Present at H.C. Wainwright Annual Global Life Sciences Conference

    NEW YORK, March 27, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center.

  • Oramed to Present at Oppenheimer's Annual Healthcare Conference
    PR Newswire2 months ago

    Oramed to Present at Oppenheimer's Annual Healthcare Conference

    NEW YORK, March 15, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenheimer's 28th Annual Healthcare Conference, being held March 20-21, 2018 at the Westin New York Grand Central in New York City. Nadav Kidron, Chief Executive Officer of Oramed, will present a corporate overview on Wednesday, March 21, 2018.

  • PR Newswire3 months ago

    Oramed Adds Two New Members to its Scientific Advisory Board

    NEW YORK, Feb. 28, 2018  /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the additions of Drs. Robert Henry and Jane Reusch to its Scientific Advisory Board. Dr. Henry is a leader in diabetes research. As a past President of the American Diabetes Association (ADA) and recipient of its Banting Medal for Scientific Achievement, among other international recognitions, his basic and clinical research funded by the National Institutes of Health (NIH) has resulted in more than 400 journal articles, chapters and books.

  • PR Newswire3 months ago

    Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension

    Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center.

  • Oramed to Present at BIO CEO Investor Conference
    PR Newswire4 months ago

    Oramed to Present at BIO CEO Investor Conference

    JERUSALEM , Feb. 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed Pharmaceuticals' CEO Issues Letter to Shareholders
    PR Newswire4 months ago

    Oramed Pharmaceuticals' CEO Issues Letter to Shareholders

    JERUSALEM , Jan. 19, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.oramed.com ) Dear Shareholders, All the hard work and dedication in 2017 has successfully positioned ...

  • ACCESSWIRE4 months ago

    Blog Exposure - AveXis Shares Details About Its Expanded Clinical Development Program for AVXS-101 for Treating Spinal Muscular Atrophy

    Stock Monitor: Oramed Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / January 18, 2018 / Active-Investors.com has just released a free research report on AveXis, Inc. (NASDAQ: AVXS ). If you want ...

  • GuruFocus.com4 months ago

    Three Diabetes Clinical Trials to Watch in 2018

    Outcomes on these three clinical trials in diabetes this year could change the way the disease is treated going into the next decade.

  • Associated Press4 months ago

    Oramed reports 1Q loss

    The Jerusalem-based company said it had a loss of 18 cents per share. The drug maker posted revenue of $611,000 in the period. Oramed shares have decreased 2 percent since the beginning of the year. The ...

  • Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule
    PR Newswire6 months ago

    Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule

    "Data from our directed preclinical NASH studies and clinical studies of ORMD-0801 in diabetics has revealed, through exploratory endpoints, that our oral insulin capsule has the ability to reduce inflammation of the liver.  Incidence of NASH is rapidly increasing, similar to the rates of increase in diabetes.  We look forward to exploring ORMD-0801 as a potential treatment for NASH," stated Oramed CEO, Nadav Kidron.

  • Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins
    PR Newswire7 months ago

    Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins

    JERUSALEM, Oct. 31, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the European Patent Office has issued to Oramed a notice of intent to grant a patent for broader claims for its invention titled, 'Methods and Compositions for Oral Administration of Proteins'. The patent covers Oramed's drugs including its oral insulin capsule ORMD-0801 which is currently in clinical development for type 1 and type 2 diabetes, as well as ORMD-0901, an oral GLP-1 analog capsule. Oramed's invention is designed to prevent the breakdown of protein-based drugs in the gastrointestinal track and promotes its crossing the small intestine.

  • PR Newswire7 months ago

    Oramed to Present at the Diabetes Technology Meeting

    JERUSALEM , October 24, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • Oramed to Present at the Disruptive Growth Showcase Conference
    PR Newswire8 months ago

    Oramed to Present at the Disruptive Growth Showcase Conference

    JERUSALEM , Sept. 25, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, ...

  • GuruFocus.com8 months ago

    Oramed Now Has a Clear Path to Market With Oral Insulin

    A look at the most recent announcement about the company's efforts to bring oral insulin to market in the US

  • Zacks Small Cap Research9 months ago

    Oramed (ORMP): Successful Meeting with FDA for Oral Insulin

    By Grant Zeng, CFA NASDAQ:ORMP The FDA Meeting Earlier today (Sept. 5, 2017), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced that it has successfully concluded a meeting with the US FDA regarding ...

  • Oramed Announces Successful Meeting with FDA for Oral Insulin
    PR Newswire9 months ago

    Oramed Announces Successful Meeting with FDA for Oral Insulin

    JERUSALEM, Sept. 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully concluded its meeting with the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the Company's novel oral insulin formulation. At the meeting, the FDA gave clear guidance that the regulatory pathway for submission of ORMD-0801, would be a Biologics License Application (BLA).  Such a pathway would grant a full 12 years of marketing exclusivity for ORMD-0801 if approved.  On top of this, an additional six months of exclusivity can be granted if the product also receives approval for use in pediatric patients. The FDA confirmed that the approach to nonclinical toxicology, CMC and qualification of excipients would be driven by their published guidance documents, consistent with the Company's expectations.  They also made specific recommendations for clinical trials designed to provide pivotal data prior to registration.

  • Oramed to Present at the Rodman & Renshaw Global Investment Conference
    PR Newswire9 months ago

    Oramed to Present at the Rodman & Renshaw Global Investment Conference

    JERUSALEM , August 29, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) ( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery ...

  • GuruFocus.com9 months ago

    3 Companies Aiming to Significantly Reduce Diabetes Treatment Costs

    Diabetes accounts for nearly 10% of US health care spending

  • Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs
    PR Newswire10 months ago

    Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs

    JERUSALEM, July 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice President of Medical Affairs. "We are very pleased to welcome Dr. Bruce on board at this pivotal time for Oramed as we prepare for the initiation of a Phase III trial for our oral insulin capsule, ORMD-0801.  Dr. Bruce will be tasked with leading all of our clinical development programs, with the specific near-term focus on bringing our oral insulin (ORMD-0801) through regulatory approval and into commercialization," stated Oramed CEO, Nadav Kidron.

  • Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017
    PR Newswire10 months ago

    Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017

    JERUSALEM, July 12, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will deliver a presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock" at the upcoming BIT'S 5th World Congress of Diabetes-2017 and BIT's 6th World Congress of Endobolism-2017 in Prague, Czech Republic. Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's PODTM technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center.

  • Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program
    PR Newswire10 months ago

    Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program

    JERUSALEM, July 11, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has agreed to schedule an End-of-Phase II meeting with Oramed for its successfully completed Phase IIb trial of its oral insulin capsule ORMD-0801 in the treatment of type 2 diabetes. The purpose of the End-of-Phase II meeting, which is expected to take place on August 31, 2017, is to review the Phase IIb results with the FDA and seek guidance from the regulatory agency on the clinical design and protocol of Oramed's upcoming pivotal Phase III trial, in preparation for filing a New Drug Application (NDA).